Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial.
Xiantong ZouRikke Mette AgesenStephen C BainFangming FuSanaz GaberyJianlin GengYiming LiYibing LuBifen LuoWuyan PangYi Taonull nullPublished in: Diabetologia (2024)
This trial was funded by Novo Nordisk A/S, Søborg, Denmark.